Skip to contentC
CNBX Pharmaceuticals Inc.
C
CNBXCNBX Pharmaceuticals Inc. Q1 2019 · 10-Q
Revenue$3.31K$3.31Kno prior Q1 2018 on file Net Income-$655.98K-$655.98Kno prior Q1 2018 on file EPS Diluted$0.01$0.01no prior Q1 2018 on file The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
CNBX Pharmaceuticals Inc. · CIK 1343009 · Engraved from SEC EDGAR
Operating Cash Flow-$667,135— Margins · derivedGross margin100.0%
Operating margin-19615.4%
Net margin-19848.0%
ended Nov 30, 2018 · filed Jan 17, 2019 · 48 d after period end